Cantor Fitzgerald analyst Steven Seedhouse downgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Overweight to Neutral.The analyst comments: "We are downgrading APLS ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE